Universität zu Köln

Paffenholz, Pia, Grein, Katharina, Heidegger, Isabel, Nestler, Tim, Grabbert, Markus, Salem, Johannes, Hellmich, Martin, Pfister, David and Heidenreich, Axel (2019). Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J. Urol., 37 (9). S. 1907 - 1917. NEW YORK: SPRINGER. ISSN 1433-8726

Full text not available from this repository.

Abstract

Purpose To identify potential risk factors for the development of venous thromboembolic events in testicular cancer patients receiving platinum-based chemotherapy. Methods We performed a retrospective analysis including 255 patients with testicular germ cell tumors who received platinum-based chemotherapy from 2003 to 2018 as a multi-center observational cohort study. Patient and tumor characteristics of patients with and without a thromboembolic event were analyzed. Results 49 (19%) patients experienced a venous thromboembolic event, with the majority representing pulmonary embolism and deep venous thrombosis (47%). There were no significant differences regarding the development of a venous thromboembolic event between first- and second-line regimes. Multivariate analysis showed an increased risk for a venous thromboembolic event in patients with clinical stage >= IIC disease (OR 2.259 [95% CI 1.105-4.618], p = 0.026), elevated serum LDH (OR 2.162 [95% CI 1.018-4.593], p = 0.045), febrile neutropenia (OR 2.973 [95% CI 1.363-6.487], p = 0.006) and central venous access (OR 3.465 [95% CI 1.068-11.243], p = 0.039). Patients suffering from a venous thromboembolic event revealed a significantly reduced overall survival (p = 0.033) during a median follow-up of 8 months [IQR 2-18]. Conclusions 19% of all patients treated by platinum-based chemotherapy due to testicular cancer suffered from a venous thromboembolic event, associated with reduced overall survival. As a result, monitoring of cancer patients at risk as well as the improvement of patients' awareness of a thromboembolic event should thus be the main goal of their treating physicians.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Paffenholz, Pia UNSPECIFIED UNSPECIFIED UNSPECIFIED Grein, Katharina UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidegger, Isabel UNSPECIFIED UNSPECIFIED UNSPECIFIED Nestler, Tim UNSPECIFIED UNSPECIFIED UNSPECIFIED Grabbert, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Salem, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Hellmich, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, David UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-143222
DOI:	10.1007/s00345-018-2598-7
Journal or Publication Title:	World J. Urol.
Volume:	37
Number:	9
Page Range:	S. 1907 - 1917
Date:	2019
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1433-8726
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CISPLATIN-BASED CHEMOTHERAPY; GERM-CELL TUMORS; THROMBOEMBOLIC EVENTS; VENOUS THROMBOEMBOLISM; RISK; DISEASE; RATES Multiple languages Urology & Nephrology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14322